CAR T-Cell Therapy Market Expected to Reach $35.9 Billion by 2032 - Allied Market Research

According to a new report published by Allied Market Research, titled, “CAR T-Cell Therapy Market: Opportunity Analysis and Industry Forecast, 2023–2032," The CAR T-cell therapy market size valued for $2.6 billion in 2022 and is estimated to reach $35.9 billion by 2032, exhibiting a CAGR of 28.5% from 2023 to 2032. Chimeric antigen receptor (CAR) T-cell therapy is a new type of cancer treatment. During this treatment, healthcare professionals reprogram the immune system to attack cancer cells. CAR T-cell therapy is a type of cell-based gene therapy, as it involves altering the genes inside T-cells to help them attack the cancer. T-cells are part of the immune system. They are a type of white blood cell with proteins on the surface that act as receptors. Healthcare professionals currently use CAR T-cell therapy to treat various types of cancer.

Factors that drive the growth of CAR T-cell therapy market include advantages of CAR T-Cell therapy over the other conventional drugs, and rise in prevalence of cancer. CAR T-cell therapy, or chimeric antigen receptor T-cell therapy, stands out as a revolutionary approach in cancer treatment, showcasing distinct advantages over conventional drugs and serving as a major driver for the growth of the market. Chimeric antigen receptor (CAR) T-cell therapy treats certain cancer by turning T-cells into more efficient cancer-fighting cells. CAR T-cell therapy is a novel targeted approach, which involves genetic engineering of T-cells to specifically target the receptors on cancer cells. The benefits of CAR T-cell therapies over conventional drugs include, the destruction of cancer cells using patients' immune system and early recovery. In addition, CAR T-cell therapy survives for a long time in the body. It has the ability to recognize and target cancer cells even if the cancer relapses. For instance, according to a 2022 report by National Cancer Institute (U.S.), tisagenlecleucel (Kymriah), was the first CAR T-cell therapy to be approved by the U.S. Food and Drug Administration, based on clinical trials demonstrating it could eradicate cancer in children with relapsed lymphoblastic leukemia.

Rise in the prevalence of cancer has emerged as a pivotal driver for the growth of the CAR T-cell therapy market. Over recent years, cancer has become a pervasive global health concern, with increasing incidence rates observed across various types of cancers. For instance, according to a 2023 report by Leukemia & Lymphoma Society, around 1,76,247 new cases of leukemia, lymphoma, and myeloma are expected to be diagnosed in 2023. This surge in cancer cases can be attributed to various factors, including lifestyle changes, environmental influences, and aging population. Conventional treatment modalities such as chemotherapy and radiation therapy, while effective to some extent, often come with severe side effects and may not provide a definitive cure. According to a 2022 report by, National Library of Medicine, Chimeric antigen receptor (CAR) T cells have been successfully used for hematological malignancies, especially for relapsed/refractory B-cell acute lymphoblastic leukemia and non-Hodgkin’s lymphoma.

However, high treatment cost stands out as a significant impediment in the widespread adoption and accessibility of CAR T-cell therapy, acting as a major restraint for the market growth. In addition, the development of new CAR T-Cell therapy is expected to present significant growth opportunity for the market.

The CAR T-cell therapy market is segmented on the basis of drug type, indication, end user, and region. On the basis of drug type, the market is classified into axicabtagene ciloleucel, tisagenlecleucel, brexucabtagene autoleucel, and others. By indication, the market is segregated into lymphoma, acute lymphocytic leukemia, and others. Depending on end user, it is fragmented into hospitals and cancer treatment centers. Region-wise, the market is analyzed across North America (the U.S., and Canada), Europe (Germany, France, the UK, and rest of Europe), Asia-Pacific (Japan, China, and rest of Asia-Pacific), and LAMEA (Latin America and Middle East and Africa).

On the basis of indication, the lymphoma segment generated maximum revenue in 2022 owing to higher number of approved CAR T-cell therapeutics for treatment of different form of lymphoma with large number of target population. The acute lymphocytic leukemia segment is expected to witness highest CAGR during the forecast period, owing to increase in awareness of CAR T-cell therapeutics for treatment of lymphoblastic leukemia and expected launch of these drug for treatment of lymphoblastic leukemia.

On the basis of end user, the hospitals segment was the highest revenue contributor to the market in 2022, owing to factors, such as well-equipped operation theatre, higher buying power, and rise in patient admission. The cancer treatment centers segment is expected to witness highest CAGR during the forecast period, owing to availability of a wide range of choice of treatment and increase in number of cancer centers in some developing nations.

Region-wise, North America generated higher revenue in 2022, owing to strong presence of key players and availability of approved therapeutics with higher adoption of CAR T-cell therapies. Europe is expected to witness highest CAGR during the forecast period owing to high prevalence rate of cancer, a large and diverse population, improving healthcare infrastructure.

KEY FINDINGS OF THE STUDY   

• By drug type, the axicabtagene ciloleucel segment held the largest share in the CAR T-cell therapy market in 2022.
• By indication, the lymphoma segment held the largest share in the CAR T-cell therapy market in 2022.
• By end user, the cancer centers segment is expected to show the fastest market growth during the forecast period.
• Region-wise, North America held the largest market share in 2022. However, Europe is expected to register fastest growth in the forecasted period.